The idea that DNA damage-deficient mechanisms promote tumorigenesis was recognised 20 years ago [5], and direct or indirect targeting of DNA damage repair pathways had emerged in cancer treatment approaches, and the clinical success of PARP inhibitors (PARPis) had made “synthetic lethal” anti-cancer therapies a new hope. Here, PARP1 is linked to cancer.